Summit Therapeutics (SMMT) Reports Q2 Loss of GBP0.02
Tweet
Share
E-mail
Get Alerts SMMT Hot Sheet
Join SI Premium – FREE
Summit Therapeutics (NASDAQ: SMMT) reported Q2 EPS of (GBP0.02).
For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
- AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue
- JPMorgan Downgrades Shenzhen Inovance Tech (300124:CH) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
